IL17A and myeloid sarcoma: Pro-inflammatory cytokines (i.e., IL-17A, IL-17F, IL-21, and IL-22) would attack the myelin and axons, leading to inflammatory injuries in MS, which could be inhibited by the regulatory T (Treg) cells5.